146882-07-7

Basic information

• Product Name: 3-(2,4-DICHLORO-PHENYL)-PROPAN-1-OL
• Synonyms: 3-(2,4-DICHLORO-PHENYL)-PROPAN-1-OL
• CAS NO: 146882-07-7
• Molecular Formula: C₉H₁₀Cl₂O
• Molecular Weight: 205.0811
• Mol File: 146882-07-7.mol

Chemical Properties

• Boiling Point: 301.977°C at 760 mmHg
• Flash Point: 124.029°C
• Appearance: /
• Density: 1.28g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: 3-(2,4-DICHLORO-PHENYL)-PROPAN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2,4-DICHLORO-PHENYL)-PROPAN-1-OL(146882-07-7)
• EPA Substance Registry System: 3-(2,4-DICHLORO-PHENYL)-PROPAN-1-OL(146882-07-7)

Safety Data

• Hazardous Substances Data: 146882-07-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H10Cl2O/c10-8-4-3-7(2-1-5-12)9(11)6-8/h3-4,6,12H,1-2,5H2

Upstream product

• 1504-59-2 3-(2.4-Dichlor-phenyl)-prop-2-en-1-ol 
• 20595-45-3 2,4-dichlorocinnamic acid 
• 42174-01-6 methyl 2,4-dichlorocinnamate 
• 874-42-0 2,4-dichlorobenzaldeyhde 
• 55144-92-8 3-(2,4-dichlorophenyl)propionic acid 

Downstream Products

• 93962-66-4 1-(3-Bromo-propyl)-2,4-dichloro-benzene 
• 1026334-46-2 Thioacetic acid S-[3-(2,4-dichloro-phenyl)-propyl] ester 
• 1026639-62-2 4-[3-(2,4-Dichloro-phenyl)-propylsulfanyl]-3-oxo-butyric acid methyl ester 
• 1027496-33-8 3-Cyano-4-[3-(2,4-dichloro-phenyl)-propylsulfanyl]-3-hydroxy-butyric acid methyl ester 
• 98581-93-2 3-(2',4'-dichlorophenyl)propionaldehyde 
• 1355026-30-0 C₁₅H₁₄Cl₂N₂O₃ 
• 1394046-58-2 (R)-2-(2,4-dichlorobenzyl)-5-oxohexanal 

Relevant articles and documents

Synthesis of optically active 4-substituted 2-cyclohexenones

Recently, Nicolaou and Baran independently synthesized optically active 4-substituted 2-cyclohexenones via an efficient LiOH-mediated intramolecular aldol condensation. Thus far, application of their cyclization approach has been limited to ketoaldehydes where the R-group is branched. It is demonstrated that the LiOH-mediated cyclization, when applied to substrates containing unbranched R-groups, results in significant erosion of optical purity. A mechanistic justification is provided, and a set of neutral, organocatalyzed conditions is identified that enables cyclization with little loss in optical purity.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.

ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme

ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of 2-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme. The best compounds, 58, 68, 71, 74 have reversible K(i)'s in the 1-3 μM range against the isolated rat enzyme. As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP- citrate lyase.